Anticoagulants and their reversal.
暂无分享,去创建一个
[1] R. Peters,et al. Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor/factor VIIa complex, in patients undergoing elective coronary angioplasty. , 2003, Journal of the American College of Cardiology.
[2] E. Hylek,et al. The risk of hemorrhage among patients with warfarin-associated coagulopathy. , 2006, Journal of the American College of Cardiology.
[3] J. C. Sørensen,et al. Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects , 2003, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[4] M Gent,et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. , 2003, The New England journal of medicine.
[5] W. S. Akers,et al. Recombinant Factor VIIa for Refractory Bleeding After Cardiac Surgery Secondary to Anticoagulation with the Direct Thrombin Inhibitor Lepirudin , 2006, Pharmacotherapy.
[6] A. Jessel,et al. Investigation of activated prothrombin complex concentrate as potential hirudin antidote in animal models. , 1995, Haemostasis.
[7] L. Aledort. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity , 2004, Journal of thrombosis and haemostasis : JTH.
[8] S. Ibbotson,et al. The Influence of Infusions of 1-Desamino-8-D-Arginine vasopressin (DDAVP) In Vivo on the Anticoaguhht Effect of Recombinant Hirudin (CGP39393) In Vitro , 1991, Thrombosis and Haemostasis.
[9] John Spandorfer,et al. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding. , 2006, Archives of internal medicine.
[10] J. Douketis,et al. Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial , 2000, The Lancet.
[11] S. Malherbe,et al. Argatroban as anticoagulant in cardiopulmonary bypass in an infant and attempted reversal with recombinant activated factor VII. , 2004, Anesthesiology.
[12] G. Raskob,et al. Hemorrhagic complications of anticoagulant treatment. , 1992, Chest.
[13] M. Tarantino,et al. The use of recombinant activated factor VII to reverse warfarin-induced anticoagulation in patients with hemorrhages in the central nervous system: preliminary findings. , 2003, Journal of neurosurgery.
[14] V. Marder,et al. DDAVP Reduces Bleeding during Continued Hirudin Administration in the Rabbit , 1996, Thrombosis and Haemostasis.
[15] S. Yusuf,et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. , 2006, JAMA.
[16] M. Brophy,et al. Anaphylactoid Reactions to Vitamin K , 2001, Journal of Thrombosis and Thrombolysis.
[17] R. Zimlichman,,et al. Efficacy and safety of a prothrombin complex concentrate (Octaplex) for rapid reversal of oral anticoagulation. , 2004, Thrombosis research.
[18] Salim Yusuf,et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. , 2006, The New England journal of medicine.
[19] G. Raskob,et al. Dose-Response Study of Recombinant Factor VIIa/Tissue Factor Inhibitor Recombinant Nematode Anticoagulant Protein c2 in Prevention of Postoperative Venous Thromboembolism in Patients Undergoing Total Knee Replacement , 2001, Circulation.
[20] J. Duguid,et al. Guidelines for the use of fresh‐frozen plasma, cryoprecipitate and cryosupernatant , 2004, British journal of haematology.
[21] S. Carlsson,et al. Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor. , 2001, Thrombosis research.
[22] F. Depasse,et al. Recombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood , 2004, Thrombosis and Haemostasis.
[23] P. D. de Groot,et al. Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux , 2003, Journal of thrombosis and haemostasis : JTH.
[24] G. Dickneite,et al. Development of an Anti-Bleeding Agent for Recombinant Hirudin Induced Skin Bleeding in the Pig , 1998, Thrombosis and Haemostasis.
[25] G. Raskob,et al. Hemorrhagic complications of anticoagulant treatment. , 2004, Chest.
[26] N. Carlson,et al. Reversal of a potent investigational anticoagulant: idraparinux with recombinant factor VIIa. , 2005, The American journal of medicine.
[27] R. Peters,et al. Recombinant factor VIIa reverses the anticoagulant effect of the long‐acting pentasaccharide idraparinux in healthy volunteers , 2004, British journal of haematology.
[28] R. Slappendel,et al. Treatment of postoperative bleeding after fondaparinux with rFVIIa and tranexamic acid. , 2005, The Netherlands journal of medicine.
[29] H G Watson,et al. Guidelines on oral anticoagulation (warfarin): third edition – 2005 update , 2006, British journal of haematology.
[30] R. Peters,et al. The impact on coagulation of an intravenous loading dose in addition to a subcutaneous regimen of low-molecular-weight heparin in the initial treatment of acute coronary syndromes. , 2003, Journal of the American College of Cardiology.
[31] B. Eriksson,et al. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. , 2002, Archives of internal medicine.
[32] J. Hirsh,et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.
[33] G. Dickneite. Prothrombin complex concentrate versus recombinant factor VIIa for reversal of coumarin anticoagulation. , 2007, Thrombosis research.
[34] H. Naritomi,et al. Predisposing factors for enlargement of intracerebral hemorrhage in patients treated with warfarin. , 2003, Thrombosis and haemostasis.
[35] B. Sullenger,et al. Nucleic acid aptamers in therapeutic anticoagulation , 2005, Thrombosis and Haemostasis.
[36] G. Raskob,et al. Fondaparinux or Enoxaparin for the Initial Treatment of Symptomatic Deep Venous Thrombosis , 2004, Annals of Internal Medicine.
[37] A. Hoeft,et al. Efficacy and Safety of Heparinase I versus Protamine in Patients Undergoing Coronary Artery Bypass Grafting with and without Cardiopulmonary Bypass , 2005, Anesthesiology.
[38] R. Linhardt,et al. Heparinase I acts on a synthetic heparin pentasaccharide corresponding to the antithrombin III binding site. , 2000, Thrombosis research.
[39] M. Wolzt,et al. Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers , 2004, Thrombosis and Haemostasis.
[40] B. Sullenger,et al. Blocking the Initiation of Coagulation by RNA Aptamers to Factor VIIa , 2000, Thrombosis and Haemostasis.
[41] H. Büller,et al. Ability of Recombinant Factor VIIa to Generate Thrombin During Inhibition of Tissue Factor in Human Subjects , 2001, Circulation.
[42] A. Daud,et al. Synthetic Heparin Pentasaccharide Depolymerization by Heparinase 1: Molecular and Biological Implications , 2001, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.
[43] C. Kessler,et al. Reversal of Warfarin-Induced Excessive Anticoagulation with Recombinant Human Factor VIIa Concentrate , 2002, Annals of Internal Medicine.
[44] F. Rosendaal,et al. Emergency Oral Anticoagulant Reversal: The Relative Efficacy of Infusions of Fresh Frozen Plasma and Clotting Factor Concentrate on Correction of the Coagulopathy , 1997, Thrombosis and Haemostasis.
[45] S. Schulman. Care of Patients Receiving Long-Term Anticoagulant Therapy , 2003 .
[46] T. Brott,et al. Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage. , 2004, Mayo Clinic proceedings.
[47] J. D. San Antonio,et al. Novel concatameric heparin-binding peptides reverse heparin and low-molecular-weight heparin anticoagulant activities in patient plasma in vitro and in rats in vivo. , 2004, Blood.
[48] G. Dehmer,et al. Recombinant platelet factor 4 for heparin neutralization. , 2004, Seminars in thrombosis and hemostasis.
[49] Persist investigators. A novel long‐acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation , 2004, Journal of thrombosis and haemostasis : JTH.